Attached files
file | filename |
---|---|
EX-32.2 - EXHIBIT 32.2 - LUMOS PHARMA, INC. | lumo-20200331x10qaxex322.htm |
EX-31.4 - EXHIBIT 31.4 - LUMOS PHARMA, INC. | lumo-20200331x10qaxex314.htm |
EX-31.3 - EXHIBIT 31.3 - LUMOS PHARMA, INC. | lumo-20200331x10qaxex313.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
☒ | Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. |
For the quarterly period ended March 31, 2020.
☐ | Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. |
For the transition period from to .
Commission File Number
001-35342
LUMOS PHARMA, INC.
(Exact name of Registrant as specified in Its Charter)
Delaware | 42-1491350 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
4200 Marathon Blvd #200
Austin, Texas 78756
(512) 215-2630
(Address, including zip code, and telephone number, including area code, of principal executive offices)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock | LUMO | The Nasdaq Stock Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer o | |
Non-accelerated filer ☒ | Smaller reporting company ☒ | |
Emerging growth company ☐ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o | ||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ý
As of May 27, 2020, there were 8,292,803 shares of the registrant’s Common Stock, par value $0.01 per share, outstanding.
EXPLANATORY NOTE
The sole purpose of this Amendment No. 1 on Form 10-Q/A (the “Amendment”) to the Quarterly Report on Form 10-Q of Lumos Pharma, Inc. (the “Company”) for the quarter ended March 31, 2020 that was filed with the Securities and Exchange Commission (the “SEC”) on June 2, 2020 (the “Original Form 10-Q”) is to add this Explanatory Note disclosing that, as previously disclosed in the Company’s Current Report on Form 8-K as filed with the SEC on May 14, 2020 (the “Form 8-K”) and in accordance with the SEC’s March 4, 2020 Order (Release No. 34-88318), as modified on March 25, 2020 (Release No. 34-88465) (collectively, the “Order”), the Company (i) is relying on the relief provided by the Order in connection with the filing of the Original Form 10-Q and (ii) was unable to file the Original Form 10-Q in a timely manner because the Company’s key accounting and legal personnel assisting the Company in the preparation of its financial statements were working remotely and therefore were unable to maintain the same ordinary course interactions with the Company’s professional advisors. As indicated above, the Company filed the Original Form 10-Q on June 2, 2020, which was within the permissible extended filing deadline pursuant to the Order and in accordance with the Company’s prior disclosure in the Form 8-K.
In addition, Part II, Item 6 of the Original Form 10-Q is hereby amended and restated in its entirety. No other changes have been made to the Original Form 10-Q. This Amendment speaks as of the original filing date of the Original Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and other than as set forth above, does not modify or update in any way disclosures made in the Original Form 10-Q.
Incorporated By Reference | ||||||
Exhibit Number | Description | Form | Filing Date | Number | Filed Herewith | |
2.1 | † | 8-K | 9/30/2019 | 2.1 | ||
3.1 | 8-K | 11/18/2011 | 3.1 | |||
3.2 | 8-K | 5/14/2013 | 3.1 | |||
3.3 | 8-K | 3/18/2020 | 3.1 | |||
3.4 | 8-K | 3/18/2020 | 3.2 | |||
3.5 | 8-K | 9/30/2019 | 3.1 | |||
4.1 | 8-K | 3/18/2020 | 4.1 | |||
4.2 | 10-Q | 5/10/2012 | 4.3 | |||
10.1 | ^ | 8-K/A | 5/29/2020 | 10.1 | ||
10.2 | ^ | 8-K/A | 5/29/2020 | 10.2 | ||
10.3 | * | 8-K | 3/18/2020 | 10.1 | ||
10.4 | * | 8-K | 3/18/2020 | 10.2 | ||
10.5 | * | 8-K | 3/18/2020 | 10.3 | ||
10.6 | * | 8-K | 3/18/2020 | 10.4 | ||
31.1 | 10-K | 6/2/2020 | 31.1 | |||
31.2 | 10-K | 6/2/2020 | 31.2 | |||
31.3 | X | |||||
31.4 | X | |||||
32.1 | # | 10-K | 6/2/2020 | 32.1 | ||
32.2 | # | X | ||||
101.INS | XBRL Instance Document | 10-K | 6/2/2020 | 101.INS | ||
101.SCH | XBRL Taxonomy Extension Schema Document | 10-K | 6/2/2020 | 101.CAL | ||
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | 10-K | 6/2/2020 | 101.LAB | ||
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | 10-K | 6/2/2020 | 101.INS | ||
101.LAB | XBRL Taxonomy Extension Label Linkbase Document | 10-K | 6/2/2020 | 101.PRE | ||
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | 10-K | 6/2/2020 | 101.DEF | ||
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | 10-K | 6/2/2020 | 101.INS |
# | The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Lumos Pharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. |
* | Indicates management contract or compensatory plan. |
† | The schedules and exhibits to the merger agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request. |
^ | Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. Certain confidential portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Copies of the unredacted exhibit will be furnished to the SEC upon request. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
LUMOS PHARMA, INC. | |
By: /s/ Richard J. Hawkins | |
Richard J. Hawkins | |
Chief Executive Officer | |
(Principal Executive Officer) | |
Date: July 7, 2020 | |
By: /s/ Carl W. Langren | |
Carl W. Langren | |
Chief Financial Officer and Secretary | |
(Principal Financial Officer) | |
Date: July 7, 2020 |